



# OncoSeek® Multi-Cancer Early Detection blood test

At OncoInv we strive to detect cancer early at low-cost. When cancer is found early, mortality and patient burden during treatment will be reduced. People deserve affordable, accessible, and available early detection of cancer. Please watch our video on OncoSeek here: [OncoSeek Video](#).

## OncoSeek: How it works

OncoSeek is a simple blood test which can detect 9 high-mortality cancer types by analysing the concentration of 7 protein tumour markers with an Artificial Intelligence (AI) powered algorithm. The algorithm analyses the **specific relations** between markers and clinical factors, drastically reducing false positives when compared to the standard analysis of multiple, individually judged, protein tumour markers.



The average sensitivity is 51.7% (37.1% to 77.6%) with a specificity of 92.9%.<sup>1</sup> The test also gives an indication for the tissue of origin which guides the following diagnostic steps.

## Straightforward

The lab analysis process is straightforward and can be performed on a widely available analysis platform using off-the-shelf reagents which are widely available. The AI based technology, combined with an off-the-shelf analysis process, results in a very **cost-effective and implementable** solution.

OncoSeek has been validated with several validation cohorts with a total of 10.000 study participants.<sup>1</sup> OncoSeek is a CE marked registered test.

## Use cases

- OncoSeek targets symptomatic patients with suspicions for cancer in primary and ambulatory care settings.
- OncoSeek also targets at-risk populations for cancer through screening, either stand alone or as a complementary tool to existing screening.

## About OncoInv

OncoInv is a social enterprise and a subsidiary of [Inspire2Live](#), a non-profit patient advocacy organisation with representatives in 40+ countries.

<sup>1</sup> [EClinicalMedicine. 2023 Jun 15;6\(1\):102041](#)



# Factsheet - OncoSeek

## Impact of multi-cancer early detection

- Reduces patient mortality
- Reduces treatment burden
- Improves quality of life
- Reduces healthcare cost

## Clinical

**Sample collection:** 8ml of venous blood collected by professional.

**Cancer types:** Breast, Colorectum, Liver, Lung, Lymphoma, Oesophagus, Ovary, Pancreas, Stomach.

- Collectively account for ~60% of cancer deaths worldwide
- Detects aggressive cancer (e.g. pancreatic)
- Detects cancers that are currently not screened for

### Use cases:

- Early detection for patients with elevated risk profile and symptoms
  - o Primary care and ambulatory care settings
- Screening for populations at risk

**Protein Tumour markers:** AFP, CA125, CA15-3, CA19-9, CA72-4, CEA, and CYFRA 21-1

**Test results:** The test results are communicated via a low-, medium- or high-risk score. In case of a high-risk score, a Tissue Of Origin is indicated.

### Performance<sup>2</sup>:

Overall sensitivity	51.7%	Overall specificity	92.9%
---------------------	-------	---------------------	-------

Concentration values are analysed by an Artificial Intelligence (AI) powered algorithm. Uniquely, the algorithm measures the interrelations between the different markers which generate superior results.

## Operational

**Lab analysis** on Roche Cobas. Analysis with off-the-shelf reagents, widely available globally.

**Algorithm analysis** is cloud based. Data is processed in the EU (Frankfurt) in compliance with the EU General Data Protection Regulation.

**Service delivery:** OncoSeek can be purchased as *full service including lab analysis* or *algorithm only*, based on local context.

## Financial

- Low-cost test
- First research into cost effectiveness of Multi-Cancer Early Detection indicates positive outcomes<sup>3</sup>
- Not for profit in low- & middle-income countries

## Contact us:

OncoInv B.V. | Duwboot 20, 3991 CD Houten, The Netherlands. | [info@oncoinv.org](mailto:info@oncoinv.org)

<sup>2</sup> [EClinicalMedicine. 2023 Jun 15;61:102041](#)

<sup>3</sup> [Br J Cancer. 2021 Nov;125\(10\):1432-1442](#)